SynthesisAdvances in therapy2025

One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis.

Tim Disher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.